Expert Consensus on Integrated Traditional Chinese and Western Medicine Diagnosis and Treatment of Chronic Atrophic Gastritis(2025)
-
摘要: 慢性萎缩性胃炎是一种临床常见病，在我国患病率极高。为帮助临床医师对慢性萎缩性胃炎进行准确、合理的诊断与治疗，本共识从中医和西医对慢性萎缩性胃炎的认识、诊断以及治疗等方面入手，旨在为慢性萎缩性胃炎的精准诊疗提供全面指导，促进慢性萎缩性胃炎研究的进一步发展。Abstract: Chronic atrophic gastritis is a common clinical disease with a high incidence and strong recurrence. To assist clinical physicians in accurately and reasonably diagnosing and treating gallstones, this consensus starts with the understanding, diagnosis, and treatment of chronic atrophic gastritis in traditional Chinese medicine and Western medicine, comprehensively and deeply introducing the recent research progress of gallstones, highlighting clinical practicality.
-
-
表 1 胃黏膜肠化(OLGIM)的分期标准
萎缩 胃体 无 轻度 中度 重度 胃窦(包含胃角) 无 0 Ⅰ Ⅱ Ⅱ 轻度 Ⅰ Ⅰ Ⅱ Ⅲ 中度 Ⅱ Ⅱ Ⅲ Ⅳ 重度 Ⅲ Ⅲ Ⅳ Ⅳ 
下载: 导出CSV
表 3 新型胃癌风险评分方法
变量名称 分值/分 年龄/岁 40~ < 50 0 50~ < 60 5 60~69 6 >69 10 性别 女 0 男 4 Hp感染 无 0 有 1 PGR ≥3.89 0 < 3.89 3 G-17/(pmol/L) < 1.50 0 1.50~5.70 3 >5.70 5 总分 23
下载: 导出CSV
表 4 消化不良症状的Likert评分
严重程度 发作程度 发作频率 1 没有 2 轻度 每周小于2次 3 中度 每周超过3次，不是每天发作 4 重度 每天发作，间歇性 5 极重度 每天发作，几乎持续性
下载: 导出CSV
-
[1] Rugge M, Correa P, Dixon MF, et al. Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading[J]. Aliment Pharmacol Ther, 2002, 16(7): 1249-1259. doi: 10.1046/j.1365-2036.2002.01301.x
[2] Dixon MF, Genta RM, Yardley JH, et al. Classification and grading of gastritis. the updated Sydney system. international workshop on the histopathology of gastritis, Houston 1994[J]. Am J Surg Pathol, 1996, 20(10): 1161-1181. doi: 10.1097/00000478-199610000-00001
[3] Plummer M, Buiatti E, Lopez G, et al. Histological diagnosis of precancerous lesions of the stomach: a reliability study[J]. Int J Epidemiol, 1997, 26(4): 716-720. doi: 10.1093/ije/26.4.716
[4] Du YQ, Bai Y, Xie P, et al. Chronic gastritis in China: a national multi-center survey[J]. BMC Gastroenterol, 2014, 14: 21. doi: 10.1186/1471-230X-14-21
[5] Lahner E, Zagari RM, Zullo A, et al. Chronic atrophic gastritis: Natural history, diagnosis and therapeutic management. A position paper by the Italian Society of Hospital Gastroenterologists and Digestive Endoscopists[AIGO], the Italian Society of Digestive Endoscopy[SIED], the Italian Society of Gastroenterology[SIGE], and the Italian Society of Internal Medicine[J]. Dig Liver Dis, 2019, 51(12): 1621-1632.
[6] Lahner E, Carabotti M, Annibale B. Atrophic body gastritis: clinical presentation, diagnosis, and outcome[J]. EMJ Gastroenterol, 2017: 75-82. doi: 10.33590/emjgastroenterol/10314623
[7] Miceli E, Lenti MV, Padula D, et al. Common features of patients with autoimmune atrophic gastritis[J]. Clin Gastroenterol Hepatol, 2012, 10(7): 812-814. doi: 10.1016/j.cgh.2012.02.018
[8] Zhang M, Liu S, Hu Y, et al. Biopsy strategies for endoscopic screening of pre-malignant gastric lesions[J]. Sci Rep, 2019, 9(1): 14909. doi: 10.1038/s41598-019-51487-0
[9] Kitahara F, Kobayashi K, Sato T, et al. Accuracy of screening for gastric cancer using serum pepsinogen concentrations[J]. Gut, 1999, 44(5): 693-697. doi: 10.1136/gut.44.5.693
[10] 中华医学会消化内镜分会. 中国早期胃癌筛查及内镜诊治共识意见(2014年, 长沙)[J]. 中华消化杂志, 2014, 34(7): 433-448. doi: 10.3760/cma.j.issn.0254-1432.2014.07.001
[11] Lenti MV, Rugge M, Lahner E, et al. Autoimmune gastritis[J]. Nat Rev Dis Primers, 2020, 6(1): 56. doi: 10.1038/s41572-020-0187-8
[12] Tozzoli R, Kodermaz G, Perosa AR, et al. Autoantibodies to parietal cells as predictors of atrophic body gastritis: a five-year prospective study in patients with autoimmune thyroid diseases[J]. Autoimmun Rev, 2010, 10(2): 80-83. doi: 10.1016/j.autrev.2010.08.006
[13] 田珂, 刘玉兰. 自身免疫性胃炎的临床特点[J]. 中华消化杂志, 2013, 33(1): 28-32.
[14] Kimura K, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis[J]. Endoscopy, 1969, 1(3): 87-97. doi: 10.1055/s-0028-1098086
[15] Rugge M, Genta RM. Staging and grading of chronic gastritis[J]. Hum Pathol, 2005, 36(3): 228-233. doi: 10.1016/j.humpath.2004.12.008
[16] Yaghoobi M, Bijarchi R, Narod SA. Family history and the risk of gastric cancer[J]. Br J Cancer, 2010, 102(2): 237-242. doi: 10.1038/sj.bjc.6605380
[17] Park YH, Kim N. Review of atrophic gastritis and intestinal Metaplasia as a premalignant lesion of gastric cancer[J]. J Cancer Prev, 2015, 20(1): 25-40. doi: 10.15430/JCP.2015.20.1.25
[18] Reddy KM, Chang JI, Shi JM, et al. Risk of gastric cancer among patients with intestinal Metaplasia of the stomach in a US integrated health care system[J]. Clin Gastroenterol Hepatol, 2016, 14(10): 1420-1425. doi: 10.1016/j.cgh.2016.05.045
[19] Eto K, Ohyama S, Yamaguchi T, et al. Familial clustering in subgroups of gastric cancer stratified by histology, age group and location[J]. Eur J Surg Oncol, 2006, 32(7): 743-748. doi: 10.1016/j.ejso.2006.04.005
[20] Bernini M, Barbi S, Roviello F, et al. Family history of gastric cancer: a correlation between epidemiologic findings and clinical data[J]. Gastric Cancer, 2006, 9(1): 9-13. doi: 10.1007/s10120-005-0350-7
[21] Oliveira C, Pinheiro H, Figueiredo J, et al. Familial gastric cancer: genetic susceptibility, pathology, and implications for management[J]. Lancet Oncol, 2015, 16(2): e60-e70. doi: 10.1016/S1470-2045(14)71016-2
[22] Rokkas T, Sechopoulos P, Pistiolas D, et al. Helicobacter pylori infection and gastric histology in first-degree relatives of gastric cancer patients: a meta-analysis[J]. Eur J Gastroenterol Hepatol, 2010, 22(9): 1128-1133. doi: 10.1097/MEG.0b013e3283398d37
[23] Masuyama H, Yoshitake N, Sasai T, et al. Relationship between the degree of endoscopic atrophy of the gastric mucosa and carcinogenic risk[J]. Digestion, 2015, 91(1): 30-36. doi: 10.1159/000368807
[24] Rugge M, de Boni M, Pennelli G, et al. Gastritis OLGA-staging and gastric cancer risk: a twelve-year clinico-pathological follow-up study[J]. Aliment Pharmacol Ther, 2010, 31(10): 1104-1111. doi: 10.1111/j.1365-2036.2010.04277.x
[25] Cho SJ, Choi IJ, Kook MC, et al. Staging of intestinal-and diffuse-type gastric cancers with the OLGA and OLGIM staging systems[J]. Aliment Pharmacol Ther, 2013, 38(10): 1292-1302. doi: 10.1111/apt.12515
[26] Yue H, Shan L, Bin L. The significance of OLGA and OLGIM staging systems in the risk assessment of gastric cancer: a systematic review and meta-analysis[J]. Gastric Cancer, 2018, 21(4): 579-587. doi: 10.1007/s10120-018-0812-3
[27] Tu HK, Sun LP, Dong X, et al. Temporal changes in serum biomarkers and risk for progression of gastric precancerous lesions: a longitudinal study[J]. Int J Cancer, 2015, 136(2): 425-434. doi: 10.1002/ijc.29005
[28] Yanaoka K, Oka M, Mukoubayashi C, et al. Cancer high-risk subjects identified by serum pepsinogen tests: outcomes after 10-year follow-up in asymptomatic middle-aged males[J]. Cancer Epidemiol Biomarkers Prev, 2008, 17(4): 838-845. doi: 10.1158/1055-9965.EPI-07-2762
[29] Tu HK, Sun LP, Dong X, et al. A serological biopsy using five stomach-specific circulating biomarkers for gastric cancer risk assessment: a multi-phase study[J]. Am J Gastroenterol, 2017, 112(5): 704-715. doi: 10.1038/ajg.2017.55
[30] Miki K. Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels-"ABC method"[J]. Proc Jpn Acad Ser B Phys Biol Sci, 2011, 87(7): 405-414. doi: 10.2183/pjab.87.405
[31] Yamaguchi Y, Nagata Y, Hiratsuka R, et al. Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels: the ABC method[J]. Digestion, 2016, 93(1): 13-18. doi: 10.1159/000441742
[32] Yoshida T, Kato J, Inoue I, et al. Cancer development based on chronic active gastritis and resulting gastric atrophy as assessed by serum levels of pepsinogen and Helicobacter pylori antibody titer[J]. Int J Cancer, 2014, 134(6): 1445-1457. doi: 10.1002/ijc.28470
[33] 王霄腾, 蔡利军, 吕宾. 血清幽门螺杆菌抗体联合胃蛋白酶原检测在胃癌和癌前病变筛查中的应用[J]. 中华消化杂志, 2016, 36(9): 582-587. doi: 10.3760/cma.j.issn.0254-1432.2016.09.002
[34] Cai QC, Zhu CP, Yuan Y, et al. Development and validation of a prediction rule for estimating gastric cancer risk in the Chinese high-risk population: a nationwide multicentre study[J]. Gut, 2019, 68(9): 1576-1587. doi: 10.1136/gutjnl-2018-317556
[35] Hu Y, Bao HB, Jin HF, et al. Performance evaluation of four prediction models for risk stratification in gastric cancer screening among a high-risk population in China[J]. Gastric Cancer, 2021, 24(6): 1194-1202. doi: 10.1007/s10120-021-01204-6
[36] Kobayashi M, Tsubono Y, Sasazuki S, et al. Vegetables, fruit and risk of gastric cancer in Japan: a 10-year follow-up of the JPHC Study Cohort I[J]. Int J Cancer, 2002, 102(1): 39-44. doi: 10.1002/ijc.10659
[37] Lee KW, Lee HJ, Surh YJ, et al. Vitamin C and cancer chemoprevention: reappraisal[J]. Am J Clin Nutr, 2003, 78(6): 1074-1078. doi: 10.1093/ajcn/78.6.1074
[38] Kim DS, Lee MS, Kim YS, et al. Effect modification by vitamin C on the relation between gastric cancer and Helicobacter pylori[J]. Eur J Epidemiol, 2005, 20(1): 67-71. doi: 10.1007/s10654-004-1027-y
[39] van den Brandt PA, Goldbohm RA. Nutrition in the prevention of gastrointestinal cancer[J]. Best Pract Res Clin Gastroenterol, 2006, 20(3): 589-603. doi: 10.1016/j.bpg.2006.04.001
[40] Li WQ, Zhang JY, Ma JL, et al. Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial[J]. BMJ, 2019, 366: 15016.
[41] Chinese Society of Gastroenterology, Chinese Study Group on Helicobacter pylori, Liu WZ, et al. Fourth Chinese National Consensus Report on the management of Helicobacter pylori infection[J]. J Dig Dis, 2013, 14(5): 211-221. doi: 10.1111/1751-2980.12034
[42] Shah SC, Piazuelo MB, Kuipers EJ, et al. AGA clinical practice update on the diagnosis and management of atrophic gastritis: expert review[J]. Gastroenterology, 2021, 161(4): 1325-1332. e7. doi: 10.1053/j.gastro.2021.06.078
[43] Rokkas T, Pistiolas D, Sechopoulos P, et al. The long-term impact of Helicobacter pylori eradication on gastric histology: a systematic review and meta-analysis[J]. Helicobacter, 2007, 12(Suppl 2): 32-38.
[44] Wang J, Xu LJ, Shi RH, et al. Gastric atrophy and intestinal Metaplasia before and after Helicobacter pylori eradication: a meta-analysis[J]. Digestion, 2011, 83(4): 253-260. doi: 10.1159/000280318
[45] Kong YJ, Yi HG, Dai JC, et al. Histological changes of gastric mucosa after Helicobacter pylorie radication: a systematic review and meta-analysis[J]. World J Gastroenterol, 2014, 20(19): 5903-5911. doi: 10.3748/wjg.v20.i19.5903
[46] de Vries AC, Haringsma J, de Vries RA, et al. The use of clinical, histologic, and serologic parameters to predict the intragastric extent of intestinal Metaplasia: a recommendation for routine practice[J]. Gastrointest Endosc, 2009, 70(1): 18-25. doi: 10.1016/j.gie.2008.08.041
[47] Lv B, Chen MT, Fan YH, et al. Effects of Helicobacter pylori eradication on atrophic gastritis and intestinal Metaplasia: a 3-year follow-up study[J]. World J Gastroenterol, 2005, 11(41): 6518-6520. doi: 10.3748/wjg.v11.i41.6518
[48] Correa P, Fontham ET, Bravo JC, et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy[J]. J Natl Cancer Inst, 2000, 92(23): 1881-1888. doi: 10.1093/jnci/92.23.1881
[49] Kodama M, Murakami K, Okimoto T, et al. Ten-year prospective follow-up of histological changes at five points on the gastric mucosa as recommended by the updated Sydney system after Helicobacter pylori eradication[J]. J Gastroenterol, 2012, 47(4): 394-403. doi: 10.1007/s00535-011-0504-9
[50] Hwang YJ, Kim N, Lee HS, et al. Reversibility of atrophic gastritis and intestinal Metaplasia after Helicobacter pylori eradication-a prospective study for up to 10 years[J]. Aliment Pharmacol Ther, 2018, 47(3): 380-390. doi: 10.1111/apt.14424
[51] Mera RM, Bravo LE, Camargo MC, et al. Dynamics of Helicobacter pylori infection as a determinant of progression of gastric precancerous lesions: 16-year follow-up of an eradication trial[J]. Gut, 2018, 67(7): 1239-1246. doi: 10.1136/gutjnl-2016-311685
[52] Yan LJ, Chen Y, Chen F, et al. Effect of Helicobacter pylori eradication on gastric cancer prevention: updated report from a randomized controlled trial with 26.5 years of follow-up[J]. Gastroenterology, 2022, 163(1): 154-162. e3. doi: 10.1053/j.gastro.2022.03.039
[53] Pinto-Sanchez MI, Yuan YH, Hassan A, et al. Proton pump inhibitors for functional dyspepsia[J]. Cochrane Database Syst Rev, 2017, 11(11): CD011194.
[54] Asaoka D, Nagahara A, Hojo M, et al. Efficacy of a potassium-competitive acid blocker for improving symptoms in patients with reflux esophagitis, non-erosive reflux disease, and functional dyspepsia[J]. Biomed Rep, 2017, 6(2): 175-180. doi: 10.3892/br.2016.828
[55] Miederer SE, Wirtz M, Fladung B. Acid neutralization and bile acid binding capacity of hydrotalcite compared with other antacids: an in vitro study[J]. Chin J Dig Dis, 2003, 4(3): 140-146. doi: 10.1046/j.1443-9573.2003.00132.x
[56] Chen HM, Li XB, Ge ZZ, et al. Rabeprazole combined with hydrotalcite is effective for patients with bile reflux gastritis after cholecystectomy[J]. Can J Gastroenterol, 2010, 24(3): 197-201. doi: 10.1155/2010/846353
[57] Santarelli L, Gabrielli M, Candelli M, et al. Post-cholecystectomy alkaline reactive gastritis: a randomized trial comparing sucralfate versus rabeprazole or no treatment[J]. Eur J Gastroenterol Hepatol, 2003, 15(9): 975-979. doi: 10.1097/00042737-200309000-00006
[58] Stefaniwsky AB, Tint GS, Speck J, et al. Ursodeoxycholic acid treatment of bile reflux gastritis[J]. Gastroenterology, 1985, 89(5): 1000-1004. doi: 10.1016/0016-5085(85)90200-8
[59] Pittayanon R, Yuan YH, Bollegala NP, et al. Prokinetics for functional dyspepsia: a systematic review and meta-analysis of randomized control trials[J]. Am J Gastroenterol, 2019, 114(2): 233-243. doi: 10.1038/s41395-018-0258-6
[60] Holtmann G, Talley NJ, Liebregts T, et al. A placebo-controlled trial of itopride in functional dyspepsia[J]. N Engl J Med, 2006, 354(8): 832-840. doi: 10.1056/NEJMoa052639
[61] Huang X, Lv B, Zhang S, et al. Itopride therapy for functional dyspepsia: a meta-analysis[J]. World J Gastroenterol, 2012, 18(48): 7371-7377. doi: 10.3748/wjg.v18.i48.7371
[62] Stanghellini V, Chan FK, Hasler WL, et al. Gastroduodenal disorders[J]. Gastroenterology, 2016, 150(6): 1380-1392. doi: 10.1053/j.gastro.2016.02.011
[63] Jones MP, Oudenhove LV, Koloski N, et al. Early life factors initiate a vicious circle of affective and gastrointestinal symptoms: a longitudinal study[J]. United European Gastroenterol J, 2013, 1(5): 394-402. doi: 10.1177/2050640613498383
[64] Talley NJ, Locke GR, Saito YA, et al. Effect of amitriptyline and escitalopram on functional dyspepsia: a multicenter, randomized controlled study[J]. Gastroenterology, 2015, 149(2): 340-349. e2. doi: 10.1053/j.gastro.2015.04.020
[65] Braak B, Klooker TK, Wouters MM, et al. Randomised clinical trial: the effects of amitriptyline on drinking capacity and symptoms in patients with functional dyspepsia, a double-blind placebo-controlled study[J]. Aliment Pharmacol Ther, 2011, 34(6): 638-648. doi: 10.1111/j.1365-2036.2011.04775.x
[66] 杨楚琪, 崔言坤, 李冀. 柴胡疏肝散加味治疗肝胃气滞证慢性萎缩性胃炎癌前病变的临床观察[J]. 中华中医药杂志, 2021, 36(1): 580-583.
[67] Li XL, Feng MX, Yuan G. Clinical efficacy of Weisu granule combined with Weifuchun tablet in the treatment of chronic atrophic gastritis and its effect on serum G-17, PGⅠand PG Ⅱ levels[J]. Am J Transl Res, 2022, 14(1): 275-284.
[68] Tang XD, Zhou LY, Zhang ST, et al. Randomized double-blind clinical trial of Moluodan(摩罗丹)for the treatment of chronic atrophic gastritis with dysplasia[J]. Chin J Integr Med, 2016, 22(1): 9-18.
[69] 姚鹏, 田晶晶, 康洪昌, 等. 荜铃胃痛颗粒联合标准四联疗法治疗慢性萎缩性胃炎伴轻中度肠上皮化生患者的效果研究[J]. 中国中西医结合外科杂志, 2021, 27(6): 855-859.
[70] 江明万, 袁野. 延参健胃胶囊治疗萎缩性胃炎的临床疗效分析[J]. 中外医学研究, 2015, 13(31): 32-33.
[71] 凡思敏. 黄芪建中汤加减治疗脾胃虚弱型(脾胃虚寒型)慢性萎缩性胃炎的系统评价[D]. 成都: 成都中医药大学, 2020.
[72] 钱舒乐, 俞赟丰, 苏思雅, 等. 黄芪建中汤加减治疗慢性萎缩性胃炎的Meta分析和试验序贯分析[J]. 河南中医, 2022, 42(3): 331-336.
[73] 于莹, 张功, 韩涛, 等. 临床常用中成药辅助治疗慢性萎缩性胃炎的网状Meta分析[J]. 中草药, 2022, 53(6): 1790-1800.
[74] 祖雅琪, 唐旭东, 于琦, 等.养胃颗粒治疗慢性萎缩性胃炎的临床综合评价[J/OL].辽宁中医杂志, 1-17[2025-02-05].
http://kns.cnki.net/kcms/detail/21.1128.r.20240418.0931.002.html .[75] 褚雪菲, 刘道龙, 韩广明. 芍药甘草汤合一贯煎加减治疗慢性萎缩性胃炎胃阴不足证的影响[J]. 中国实验方剂学杂志, 2021, 27(18): 107-112.
[76] 周炜, 李玉潇, 张艺璇, 等. 经络诊察取穴法针刺治疗慢性萎缩性胃炎疗效观察[J]. 中国针灸, 2020, 40(9): 928-932.
[77] 曹雯, 张靖娟, 林晨辉, 等. 隔姜灸治疗慢性萎缩性胃炎的临床研究[J]. 上海针灸杂志, 2021, 40(8): 950-953.
[78] 姬旭, 刘璐, 杜鑫, 等. 火针速刺联合温针灸治疗脾胃虚寒型慢性萎缩性胃炎的疗效及对血清G17、PGI及PGR水平影响[J]. 针灸临床杂志, 2022, 38(4): 32-36.
[79] 赵楠, 陆玉婷, 霍永利, 等. 化浊解毒方联合穴位贴敷治疗慢性萎缩性胃炎的临床研究[J]. 中国中西医结合消化杂志, 2021, 29(9): 599-604. doi: 10.3969/j.issn.1671-038X.2021.09.01
[80] 白文筠, 梁峻尉, 苗秀明, 等. 穴位埋线联合四联疗法对幽门螺旋杆菌(+)脾胃虚弱证慢性萎缩性胃炎的疗效观察[J]. 针刺研究, 2022, 47(6): 537-543.
[81] 王婷婷, 张月苗, 张学智, 等. 荆花胃康胶丸联合PPI三联疗法对幽门螺杆菌阳性慢性萎缩性胃炎的效果: 多中心随机对照临床研究[J]. 中华医学杂志, 2013, 93(44): 3491-3495.
[82] 马盼盼, 孟立娜, 王曼彤, 等. 铋剂四联序贯荆花胃康胶丸治疗伴有消化不良症状的幽门螺杆菌感染初治患者的多中心随机对照研究[J]. 中华医学杂志, 2021, 101(26): 2060-2065.
[83] Haruma K, Kato M, Inoue K, et al. Kyoto Classification of Gastritis[M]. Tokyo: Nihon Medical Center, 2017.
[84] De Luca L, Zagari RM, Pozzato P, et al. Measuring dyspepsia: a new severity index validated in Bologna[J]. Dig Liver Dis, 2004, 36(12): 806-810.
[85] Whiting JL, Sigurdsson A, Rowlands DC, et al. The long term results of endoscopic surveillance of premalignant gastric lesions[J]. Gut, 2002, 50(3): 378-381.
[86] Nam JH, Choi IJ, Cho SJ, et al. Association of the interval between endoscopies with gastric cancer stage at diagnosis in a region of high prevalence[J]. Cancer, 2012, 118(20): 4953-4960.
[87] 国家消化系疾病临床医学研究中心(上海). 中国胃黏膜癌前状态和癌前病变的处理策略[J]. 中华消化杂志, 2020, 40(11): 731-741.
-
计量
- 文章访问数: 688
- 施引文献: 0